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ABSTRACT
Background: The identification of anaplastic lymphoma kinase (ALK) 
rearrangements is found in approximately 5% of non-small-cell lung cancers 
(NSCLCs). However, the development of liquid biopsies as a diagnostic tool is less 
developed in these cases. This study investigates the use of CTCs during treatment, 
together with an extended follow-up to correlate with clinical evolution.
Patients and Methods: A total of 13 patients out of a cohort of 212 patients 
with lung adenocarcinoma, presented ALK rearrangements (6%) confirmed by tumor 
biopsy. A total of 60 serial blood samples were collected from these patients who 
were prospectively enrolled in the study.
Results: All patients had a positive CTC count at baseline (mean = 3). The median 
follow-up was 9 months (range 1-17 months). Three patients underwent surgery and 
their CTC counts decreased after the procedure but still remained detectable. After 
radiotherapy, 3 cases showed an average decrease of 5 CTCs. A total of 6 patients 
were treated with ALK inhibitors and a partial response was observed in 3 of them, 
who also presented decreased CTC counts. The other 3 patients presented primary 
resistance, and their CTC counts were higher than those obtained prior to progression.
Conclusion: We believe that the use of CTCs for dynamic monitoring of NSCLC 
with ALK rearrangement and to detect disease persistence or recurrence may be a 
reliable technique. CTC counts may also have potential use to monitor the efficacy of 
ALK inhibitors, facilitating detection of resistance to treatment.
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INTRODUCTION
Personalized medicine opens new opportunities 
for more accurate diagnosis, more sensitive and frequent 
disease monitoring along with more personalized therapeutic 
strategies at patient level, but surely need to be integrated 
with other specific aspects of routine clinical practice.
In Oncology, the evaluation of response to treatment and 
accurate predictions of survival are key factors for the effective 
control of the disease, as well as the design of treatment plans 
and the development of future treatments. However, the 
methods currently used to represent this response are relatively 
poor as, in order to evaluate the efficacy of a specific treatment, 
we have to wait for correlation with images over several 
cycles. This process can take several months and is not always 
completely accurate when determining the extent of disease. 
Despite living in the era of great genomic development, 
clinical foundations remain anchored in tight monitoring 
and evaluations based on tumor size and morphology, an 
environment in which liquid biopsy could undoubtedly have 
a pivotal role.
EML4-ALK is a fusion-type protein-tyrosine kinase 
generated through a recurrent chromosome rearrangement, 
a small inversion within the short arm of chromosome 
2, inv(2)(p21p23) [1]. The identification of ALK 
rearrangements, found in approximately 5% of non-small-
cell lung cancers (NSCLCs), and the success of tyrosine-
kinase inhibitors (TKI) (crizotinib, ceritinib, alectinib and 
brigatinib), have provided a breakthrough similar to the 
discovery of EGFR mutations and treatment [2].
The majority of patients with ALK NSCLC that initially 
respond to treatment with crizotinib inevitably relapse, after 1 
or 2 years, with multiple mechanisms of resistance and distinct 
patterns that depend on each ALK inhibitor [3, 4].
Unlike NSCLC with EGFR mutation, where ctDNA 
biomarker analyses can be used, no such methods have 
yet been developed to identify ALK rearrangements. Few 
studies have analyzed circulating tumor cells (CTCs), 
which can be isolated from these patients in various 
situations and statuses. However, sample sizes were very 
small and lacked clinical follow-up [5].
There are currently no studies investigating the 
dynamic changes of ALK status in plasma in the context 
of daily clinical practice.
The aim of this study was to investigate and determine 
a non-invasive method based on liquid biopsy using CTCs 
obtained from multiple blood extractions, performed during 
treatment and prolonged follow-up, which would allow us to 
identify variations and correlate them with clinical evolution.
RESULTS
Patient demographics
A total of 13 patients with ALK rearranged NSCLC 
were enrolled in the study. Patient characteristics are 
described in Table 1. The median age at the time of 
diagnosis was 55 (range 36-64) years; 6 were male and 
7 female. More than half of the patients had a history of 
smoking habit, 7 of them current smokers and 1 former 
smoker. The other 5 patients were never smokers. All 
patients presented a performance status of 0-1 at diagnosis. 
At the time of inclusion in the study, 11 patients had stage 
IV disease. One patient had locally advanced and another 
localized disease.
During the follow-up period, three patients 
underwent tumor-related surgery with radical intent, and 
8 patients received radiotherapy with either radical or 
palliative intent.
Regarding the first systemic treatments administered 
within the study, 12 patients received chemotherapy based 
on a platinum doublet, with neoadjuvant intent in 1 case 
and adjuvant in another. Six patients were treated with 
ALK inhibitors, crizotinib and ceritinib, sequentially in 
4 cases, while 2 other patients were already receiving 
crizotinib as a single inhibitor at the time of data 
collection.
Detection and kinetics of CTCs in ALK 
rearranged patients
A mean of 5 blood samples (range 1-10) per patient 
were collected for CTC analyses. All 13 patients had a 
positive CTC count at baseline, with 1 or more CTCs 
in 10 ml of blood (range 1-6). Median follow-up was 9 
months (range 1-17 months). A mean CTC count of 3 
was presented at diagnosis by patients with localized and 
locally advanced stages (n = 2, range 1-6) as well as those 
in metastatic stages (n= 11, range 2-6) (Figure 1).
Of the three patients (1, 9, and 10) who underwent 
surgery, all presented a decreased CTC count after the 
procedure but still remained positive. Notably, patient 
9 (stage IIA), presented 6 CTCs/10 ml after adjuvant 
platinum-vinorelbine-based therapy, and relapsed 10 
months later. Patient 10 (stage IV) underwent surgery with 
radical intent due to oligometastatic involvement from a 
single brain lesion. A total of 3 CTCs were determined 
after complete resection, but suffered progression at 
brain level 4 months later. At the time of progression the 
patient presented a CTC count of 15/10ml (Figure 2). 
Patient 1 (stage IIIA) underwent surgery after neoadjuvant 
treatment and subsequently a right upper lobe lobectomy. 
Following surgery the patient was detected 1 CTC/10ml, 
and was disease free after 15 months.
Out of the 8 patients treated with radiotherapy, 
pre- and post-procedure samples were obtained from 3 of 
them, and an average decrease of 5 CTCs (range 2-9) was 
observed, possibly indicative of partial response.
A total of 6 patients were treated with ALK 
inhibitors. CTCs analyses were obtained from all of them 
before and during treatment. The 3 patients who displayed 
a partial response (Patient 2, treated with ceritinib, and 
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patients 3 and 7 treated with crizotinib) also presented a 
decrease in the number of CTCs (mean=4, range 3-5). The 
two patients treated with crizotinib presented increased 
CTC counts at the time of progression (7 and 6 CTCs, 
respectively) (Figure 3).
The remaining 3 patients treated with ALK 
inhibitors presented a primary resistance to treatment; 
patient 11 died after receiving treatment for 10 days 
with ceritinib due to a leptomeningeal carcinomatosis, 
while patients 6 and 13 suffered from bone and brain 
progression, and presented CTC counts higher than prior 
to progression. Mean count of CTCs in these 3 patients 
previous ALK-inhibitor treatment was 2.
DISCUSSION
NSCLC is the leading cause of cancer death in 
developed countries [6]. In the case of metastatic disease, 
5-year survival remains under 15% [7], thus representing a 
major public health problem. In order to better understand 
the molecular biology underlying the tumor process, 
research in the last decade has focused on the study of 
the genetic alterations of these tumors, finding frequently 
altered genes that affect several signaling pathways 
involved in proliferation, apoptosis suppression, cell 
survival, or angiogenesis, among others. These advances 
have allowed the development of targeted therapies that 
inhibit some of these signaling pathways such as ALK 
or EGFR inhibitors. These new drugs have achieved 
significant improvements in survival, as well as lower 
toxicities associated [8].
Liquid biopsy emerges as a useful tool to provide 
the genetic landscape of primary and metastatic cancer 
lesions. Circulating free DNA (cfDNA), exosomal RNA, 
CTCs or tumor-educated platelets, offer the potential for 
early diagnosis, identification of therapeutic targets, real-
time monitoring of therapies and resistance mechanisms, 
and understanding metastasis development in cancer 
patients [9].
Several ALK TKI resistance mechanisms have been 
identified since the discovery of ALK as a therapeutic target 
in NSCLC. Traditionally, sequencing analyses of pre-TKI 
and post-TKI tumor biopsies, followed by the validation of 
candidate resistance mechanisms, have been commonly used. 
To overcome the known limitations in biopsy specimens 
with regard to tumor quantity and quality, recent studies 
have used patient-derived cell lines and xenograft models, 
which have led to the identification of two major classes of 
ALK TKI resistance mechanisms [10]: on one hand ALK-
dependent, “on-target” mechanisms, which include ALK 
secondary resistance mutations or amplification, where the 
tumor cell dependency on ALK signaling persists. In the 
recent study published by Gainor et al [4], a specific profile 
of secondary ALK resistance mutations has been described, 
TKI-treatment dependent. Secondary ALK mutations were 
observed in 20-30% patients progressing on crizotinib, versus 
Table 1: Patient demographics
Age at 
diagnosis
Sex Smoking status Nº of pack-
years
Diagnosis 
WHO PS
Tumor stage 
at baseline
First systemic 
treatment received
Surgery Radiotherapy ALK 
inhibitor
Number of blood 
samples recovered
Range of 
CTCs
Patient 
1
64 Male Current smoker 10 0 IIIA Chemotherapy Yes Yes No 5 1-6
Patient 
2
36 Female Never smoker 0 1 IVB Chemotherapy No Yes Crizotinib & 
Ceritinib
10 0-8
Patient 
3
62 Male Current smoker 50 0 IVA ALK inhibitor No No Crizotinib 9 0-7
Patient 
4
61 Male Current smoker 60 1 IVA Chemotherapy No No No 2 2
Patient 
5
66 Female Former smoker 5 1 IVA Chemotherapy No No No 5 0-5
Patient 
6
52 Male Current smoker 20 0 IVB Chemotherapy No Yes Crizotinib & 
Ceritinib
9 0-6
Patient 
7
45 Female Never smoker 0 0 IVB Chemotherapy No Yes Crizotinib 3 0-3
Patient 
8
54 Female Current smoker 20 0 IVB Chemotherapy No No No 2 2-4
Patient 
9
54 Female Never smoker 0 0 IIA Chemotherapy Yes Yes No 4 0-6
Patient 
10
60 Female Never smoker 0 0 IVB Chemotherapy Yes Yes No 6 3-15
Patient 
11
42 Male Never smoker 0 0 IVB Chemotherapy No Yes Crizotinib & 
Ceritinib
2 2-3
Patient 
12
60 Male Current smoker Pipe smoker 0 IVB Chemotherapy No Yes No 2 0-6
Patient 
13
61 Female Current smoker 40 0 IVB Chemotherapy No No Crizotinib & 
Ceritinib
1 2
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50-70% patients treated with 2nd generation ALK TKI 
(ceritinib, alectinib, and brigatinib). Of note, the frequency of 
G1202R mutation was significantly higher (35-60%) among 
2nd generation ALK TKI, compared to crizotinib (10%). 
ALK amplification appears to be an infrequent mechanism 
of resistance to second-generation ALK TKIs, although 
the exact frequency has not been determined. On the other 
hand, ALK-independent, “off-target” mechanisms, includes 
activation of bypass tracks and lineage changes, where the 
tumor cells effectively escape dependency on ALK which 
include: HER receptor family activation bypass mechanisms, 
MET amplification, MEK reactivation, PIK3CA mutation, 
KIT amplification, IGF1R activation, and SRC activation. 
Our study demonstrates that serial detection of 
CTCs in ALK-rearranged patients may serve as a helpful 
tool to monitor the response to treatment with both 
chemotherapy and TKIs. However, this hypothesis should 
be further tested in a larger sample of patients.
In a series of 5 patients, Ilie et al. [5] demonstrated that 
ALK rearrangement could be detected in CTCs; however, the 
study did not include a serial follow-up. A study by Pailler 
et al. [11] provided limited information about 5 patients 
undergoing treatment with crizotinib, but it was not specified 
as to whether there was serialization or how many samples 
had been extracted in each case. The work by Tan et al. 
[12], which examined the relevance of CTCs as a surrogate 
to biopsy, only included one case with sequential CTC 
information. The majority of studies published up to date are 
limited to exploring the possibility and reliability of CTCs in 
this population without any additional clinical implications.
We believe that our study provides several relevant 
innovations. Firstly, we were able to detect CTCs during 
initial, locally advanced and metastatic disease in all the 
cases, and without detecting differences in the number of 
CTCs, according to the stage of the disease. In addition, 
relapse of the disease was observed in all the cases where 
CTCs remained detectable, including initial stage patients 
receiving adjuvant treatment. On the other hand, variations 
were observed in the number of CTCs isolated depending 
on the clinical status with 100% specificity even in clinical 
scenarios of apparent oligometastatic disease which later 
proved not to be so.
The number of patients included in our study, 
although limited, is higher than in other published series, 
Figure 1: Circulating tumor cells (CTCs) isolated from peripheral blood samples obtained from patients diagnosed 
with stage IV lung adenocarcinoma presenting ALK rearrangements. Cells are detected using double density gradient and 
enrichment through positive selection by an immunomagnetic technique and subsequent staining with monoclonal antibodies. (A) Field 
contains numerous CTCs with positive intracellular staining by cytokeratin. CK+FITC (green). (FITC: fluorescein isothiocyanate). 
(B) Cytometric dot-plot showing CTCs with characteristic phenotype: EPCAM positive epithelial surface staining (CD326-PE) (PE: 
phycoerythrin) and CD45 negative (CD45-APC) (APC: alophycocianin). (C, D & E) CTCs corresponding to patient 2. Coexpression of 
epithelial markers CK+ (green) EPCAM+ (red). (F, G & H) CTCs corresponding to patient 10. Coexpression of epithelial markers CK+ 
(green) EPCAM+ (red). (E & H) CTC detection by phase-contrast microscopy. The magnification bar corresponds to 50 microns in figure 
A and 15 microns in figures C, D, E, F, G & H.
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Figure 3: Correlation between CTCs and clinical course in patient 3. (A) A 62-year-old male patient, diagnosed with lung 
ALK-rearranged adenocarcinoma cT1 N1 M1a, stage IV, with pleural disease at diagnosis. In July 2015 the patient starts treatment based on 
crizotinib. The pre-treatment CTCs count was 6. (B) In September 2015, a partial response of pleuropulmonary involvement was observed. 
A total of 5 CTCs were measured at that time. (C) In February 2016 a greater partial response was observed with 1 CTC at that time. (D) The 
response lasted until November 2016, with the appearance of new lung nodules and disease progression. This progression was associated 
with an increase of 7 CTCs.
Figure 2: Correlation between CTCs and clinical course in patient 10. (A) A 60-year-old female patient diagnosed with 
an ALK-rearranged adenocarcinoma cT2 N0 M1, stage IV, for a single brain lesion. After complete excision of the brain lesion, the 
diagnosis was obtained. The determination prior to the subsequent pulmonary surgery, performed in February 2016, was 4 CTCs. (B) 
After right lung lobectomy, the patient maintained CTCS positivity with a count of 3. Adjuvant chemotherapy was based on 4 cycles of 
carboplatin-paclitaxel. (C) In June 2016 15 CTCS were determined, correlating with a single brain progression in radiated corona. (D) After 
radiosurgery, a response of the lesion was correlated with a decrease in the number of CTCs. (E) In December 2016, a partial response of 
the brain lesion was maintained, with a greater decrease in CTCs without progression of the disease at a systemic level.
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which may be relevant considering the low frequency of 
this tumor subtype. Another strength is the high number 
of samples collected per patient, being approximately one 
every three months coinciding with a clinical evaluation.
To date, the CellSearch® (Veridex LLC) system is 
the only approved methodology by the U.S. Food and Drug 
Administration (FDA), for baseline CTC enumeration as 
an aid to prognosis and treatment monitoring in colorectal, 
breast and prostate cancers [13].
This methodology used in our study allows us to 
identify almost every CTC by the epithelial adhesion 
molecule EpCAM, which has been shown to exhibit a 
high frequency of expression in most human cancers, 
and up to 80% expression in lung adenocarcinomas 
[14]. Surface biomarking was reinforced in order to 
avoid false negatives, so an intracellular labeling with 
pan-cytokeratin-specific antibody was added to allow 
a greater specificity. This way, we prevented epithelial 
surface antigens loss that may occur in some CTCs due 
to epithelial-mesenchymal (EMT) transition [15]. In this 
sense, marking with mesenchymal markers (vimentin) was 
performed on the isolated cells, obtaining negative results 
Figure 4: Sensitivity determination for CTC detection. Blood sample from healthy patient spiked with a specific number of 
epithelial cells from A549 tumor cell line. (A) Green-tagged epithelial cell with Cytokeratin. Nuclear staining with To-Pro 3 is observed in 
blue for identification of viable cells. The flow cytometry dot- plot shows CD326 (EpCAM) positive and CD45 negative after identification 
of mononuclear viable cells based on the selection of DRAQ5 positive event.
Figure 5: Cytomorphological differences between lymphocytes and CTCs. Blood samples of patients where CTCs and 
lymphocytes are observed. (A, D) labelling with CD45 for lymphocyte detection. (B, E) labelling with Cytokeratin for CTC 
detection. (C, F) merge of both labels. Bars in figure B below CTC correspond to 16 microns and bars figure A in lymphocyte 
correspond to 8 microns.
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in our series of patients. Recently, several authors have 
assessed the expression of mesenchymal markers in CTCs 
from different tumors [16–18].
In our opinion, our results open a window of 
opportunity to perform more and larger studies, and that 
this technique could be used both for monitoring and 
planning TKI treatment sequences, especially considering 
the complexity and heterogeneity of this disease, in which 
up to ten distinct ALK variations have been described and 
all have significantly different progression free survivals 
(PFS). Yoshida et al. published a study evaluating 
whether the efficacy of crizotinib differs between ALK 
variants [19]. Patients were divided into ALK variant 1 
and non-variant 1, and similar clinical characteristics were 
observed in both. Differences were found in the median 
PFS, which was significantly longer in patients with 
variant 1 than in patients with non-variant 1 (11.0 months 
vs 4.2 months, respectively; p<0.05). In this case, CTCs 
could evaluate the disease response status independently 
of the variant.
In addition, as treatment rechallenge can induce a 
subsequent response in some patients, liquid biopsy could 
be useful for follow-up monitoring of such cases as well 
as in others where non-invasive response monitoring 
may be crucial [20]. In the near future, genotyping with 
clinical information and personalized medicine with 
next generation sequencing may be able to transform our 
perspectives of the disease [21].
We believe that CTC analyses could be used to 
monitor the efficacy of each ALK inhibitor and even 
determine their sequencing, thereby guiding the clinical 
management of each case and facilitating detection of 
resistance to treatment.
MATERIALS AND METHODS
Patients
Out of a cohort of 212 patients with lung 
adenocarcinoma, 13 patients (6%) presented ALK 
rearrangements, all confirmed by tumor biopsy. These 
patients were prospectively enrolled in the study between 1st 
June 2015 and 1st January 2017. Briefly, eligible patients were 
adult males and females with a pathologically confirmed 
diagnosis of NSCLC tumors harboring an ALK translocation 
in primary tumor tissue. All cases were confirmed by 
fluorescence in situ hybridization (FISH) using Vysis 
ALK Break Apart FISH Probes for the detection of ALK 
chromosomal translocation. Written informed consent was 
obtained from every patient prior to participation.
Study design
A complete staging work-up was performed prior 
to recruitment and in accordance with the 7th edition of 
the AJCC Cancer Staging Manual. A total of 60 serial 
blood samples were collected at various timepoints 
throughout the study, including at diagnosis, prior to 
and after surgery or radiotherapy (if applicable), and 
at radiological and/or clinical reevaluation during 
follow-up. The first sample collected was defined as the 
baseline for each patient, either upon diagnosis in local 
or locally advanced patients or upon treatment initiation 
in metastatic patients.
Patient information concerning demographic and 
clinical-pathological features together with the type of 
treatment and treatment outcome was obtained from 
electronic health records (EHR). All variables were 
recorded in a database specifically designed for the 
project and based on REDCap (Research Electronic Data 
Capture) [22]. This database was integrated with external 
sources such as the hospital’s EHR. REDCap is a secure, 
web-based application designed to support data capture 
for research studies and, among other features, provides 
validated data entry and audit trails.
Data modeling and dictionary creation were 
performed together with configuration of crossed data 
validation between fields to increase the quality of 
collected data. These steps can also serve as a basis for 
future studies that may require integration of multiple 
information sources and dynamic data generation over a 
period of time.
The study was approved by the Hospital 
Universitario Puerta de Hierro Ethics Committee (internal 
code PI/144-14) and was conducted in accordance to the 
precepts of the Helsinki Declaration.
All the authors served as the advisory board and 
participated in all phases of the study, including protocol 
design, data collection and analysis.
Isolation and enumeration of circulating tumor 
cells
Blood samples (10ml) for CTC analysis were 
collected in CellSave Preservative Tubes (CellSave 
Preservative Tubes; Veridex LLC). A total of 10 blood 
samples from healthy volunteers without evidence of an 
epithelial malignancy served as negative controls. Briefly, 
samples were processed using a double density gradient 
with 5ml of Histopaque 1077 (Sigma -Aldrich) over 
an equal volume of Histopaque 1119 (Sigma -Aldrich) 
to recover the mononuclear cell and granulocyte cell 
fractions. The tubes were centrifuged at 700g for 30 
minutes. Both fractions were transferred into a new tube 
and washed with 10ml of PBS and centrifuged at 300g for 
10 minutes [23].
Magnetic cell separation and analysis of CTCs 
by flow cytometry and confocal microscopy
CTC enrichment was performed by selective 
positive immunomagnetic cell separation using EPCAM 
Oncotarget59415www.impactjournals.com/oncotarget
microbeads (Miltenyi-Biotec, Germany). The magnetically 
labelled cell suspension was then purified and enriched in 
a magnetic field using an AutoMACS (Miltenyi Biotec) 
magnetic separator.
After capture and immunomagnetic enrichment, 
fluorescent reagents were added for intracellular and 
extracellular phenotypic identification of CTCs by flow 
cytometry and confocal microscopy. The cells were 
fluorescently labeled with anti-human CD45-APC 
(Clone: 5B1), anti-human CD326-Epcam PE (Clone: 
HEA-125), a nuclear dye to detect viable cells and 
anti-Cytokeratin-FITC (CK3-6H5) (Miltenyi Biotec) 
antibodies. Intracellular staining for Cytokeratin detection 
(by confocal microscopy) was performed by fixing in 
methanol and washing in PBS, samples were incubated 
for 1 hour at room temperature and then mounted in PBS/
Glicerol.
To determine the sensitivity of our technique, 
blood samples from healthy individuals was mixed 
with a variable and decreasing number of tumor cells 
(5000, 1000, and 500) from lung and colon cancer cell 
lines (A549, HCT116). In Figure 4 cytokeratin-labelled 
epithelial cells are detected by confocal microscopy, 
together with whole blood cells, additionally to the 
flow cytometry dot-plot with phenotypically CD326 
(EPCAM) positive and CD45 negative. Following the 
characterization and subsequent isolation of the CTCs, 
the enriched fraction was labelled using multicolor 
immunofluorescence methods to characterize its 
phenotypic profile: EPCAM + / CD45- / nuclear marker 
+ versus the CD45 positivity of blood leukocytes. In 
addition, an intracellular cytokeratin + expression study 
and cytomorphological characterization of CTCs were 
added.
The method used for enriching and isolating 
CTCs in this study combines several technologies based 
on the identification and characterization of CTCs by 
their physical (size, density) and biological properties 
(expression of surface molecules, viability…), using two 
technological platforms: flow cytometry and confocal 
microscopy. It was found that it fulfilled the criteria 
defined by Meng and collaborators to identify a circulating 
tumor cell (high nuclear/cytoplasmic ratio and cells larger 
than white blood cells) and validated the proposed method 
against other systems where a morphological study is not 
performed (Figure 5) [24].
Samples were analyzed by flow cytometry using a 
MACSQuant flow cytometer (Miltenyi-Biotec) equipped 
with three solid state lasers which allow simultaneous 
detection of up to 10 parameters. The flow cytometry 
dot-plots were generated by logarithmic amplification of 
fluorescent emission of single viable cells. Microscopy 
images were collected with a TCS SP5 confocal 
microscope (Leica Microsystems, Wetzlar, Germany) 
equipped with 20× 0.4 lens and 3x optical zoom. The three 
channels of fluorescence were acquired sequentially with 
the excitation and emission parameters for cytokeratin 
signal (488 nm, 500-540 nm), EPCAM (546 nm, 557-
572nm), and CD45 (633 nm, 645-750 nm).
Data analysis was performed using sensitive 
MACS Quantify TM Software v2.5 (Miltenyi Biotec) and 
Leica LASFlite software (Leica Microsystems, Wetzlar, 
Germany).
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